Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds

Affiliations

Editorial

Travis H Turner et al. Mov Disord. 2023 Jul.

. 2023 Jul;38(7):1125-1126.

doi: 10.1002/mds.29498.

¹ Department of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA.

No abstract available

Keywords: Parkinson's disease; cannabis; cognition.

Comment on

Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Domen CH, Sillau S, Liu Y, Adkins M, Rajkovic S, Bainbridge J, Sempio C, Klawitter J, Leehey MA. Domen CH, et al. Mov Disord. 2023 Jul;38(7):1341-1346. doi: 10.1002/mds.29447. Epub 2023 May 22. Mov Disord. 2023. PMID: 37212386 Clinical Trial.

1. Urbi B, Corbett J, Hughes I, et al. Effects of cannabis in Parkinson's disease: a systematic review and meta-analysis. J Parkinsons Dis 2022;12(2):495-508.
1. Holden SK, Domen CH, Sillau S, Liu Y, Leehey MA. Higher risk, higher reward? Self-reported effects of real-world cannabis use in Parkinson's disease. Mov Disord Clin Pract 2022;9(3):340-350.
1. Yenilmez F, Fründt O, Hidding U, Buhmann C. Cannabis in Parkinson's disease: the Patients' view. J Parkinsons Dis 2021;11(1):309-321.
1. Bega D, Simuni T, Okun MS, Chen X, Schmidt P. Medicinal cannabis for Parkinson's disease: practices, beliefs, and attitudes among providers at National Parkinson Foundation centers of excellence. Mov Disord Clin Pract 2016;4(1):90-95.
1. Kluger B, et al. Parkinson's Foundation Consensus Statement on the Use of Medical Cannabis for Parkinson's Disease. 2020. https://www.parkinson.org/sites/default/files/documents/medical_cannabis.... Accessed May 19, 2023.